2019 Update of the European AIDS Clinical Society Guidelines for Treatment of People Living With HIV Version 10.0

L Ryom; A Cotter; R De Miguel; C Béguelin; D Podlekareva; JR Arribas; C Marzolini; PGM Mallon; A Rauch; O Kirk; JM Molina; G Guaraldi; A Winston; S Bhagani; P Cinque; JD Kowalska; S Collins; M Battegay


HIV Medicine. 2020;21(10):617-624. 

In This Article

The European AIDS Clinical Society (EACS) Guidelines

As several countries are lacking or infrequently update national HIV guidelines, the EACS Guidelines have since 2005 provided recommendations that are independent of geographical region and levels of care. Acknowledging that HIV care extends far beyond antiretroviral treatment (ART), the EACS Guidelines also provide guidance on several other key aspects related to HIV management.

In 2019, the EACS Guidelines underwent major revisions of all sections.[1] One of the most essential changes includes a new panel focusing on drug–drug interactions (DDIs) and other prescribing issues in people living with HIV (PLWH) in acknowledgement of the increased ageing of PLWH and increasing risks of polypharmacy.

Bictegravir (BIC) and doravirine (DOR) were released since the last major revision and have been included in all sections. In addition, older drugs that are now rarely used, including several older boosted protease inhibitors (PI/bs), didanosine and stavudine, were removed from most sections.

To ensure easy access to the Guidelines, a new format in the form of an interactive web-based version was introduced (https://eacs.sanfordguide.com) in 2019. The Guidelines remain available in print as a booklet, online as a pdf (https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf) and as a free App for IOS and Android devices produced with the Sanford Group. The EACS Guidelines are translated into Chinese, French, German, Japanese, Portuguese, Russian and Spanish.